Your session is about to expire
← Back to Search
RIC Regimen for Nonmalignant Diseases (RIC Trial)
RIC Trial Summary
This trial will use a RIC regimen in an effort to improve outcomes in patients with non-malignant diseases.
RIC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRIC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RIC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 6 months and 25 years old.I do not have any untreated infections.My heart, kidneys, and liver meet the health requirements, and I don't have any active infections.I have IPEX syndrome, Sickle cell, Thalassemia major, or Bone marrow failure.I have a severe immune system disorder like HLH, SCID, or Wiskott-Aldrich syndrome.
- Group 1: RIC: Distal Campath
- Group 2: RIC:Intermediate Campath
- Group 3: RIC: Mini Busulfan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals aged 30 and over being recruited for this experiment?
"This research is open to participants aged between 6 months and 25 years old."
What is the number of participants currently enrolled in this clinical experiment?
"Yes, the details posted to clinicaltrials.gov confirm that recruitment is actively underway for this medical trial. Initially published on January 1st 2008 and updated most recently March 8th 2022, 50 individuals are being sought from one research site."
Is enrollment for this experiment open at the moment?
"Affirmative. According to clinicaltrials.gov, this medical study is still recruiting patients - first posted on January 1st 2008 and last updated March 8th 2022. There are 50 participants needed at one trial site."
Has the research concerning RIC:Intermediate Campath been extensive?
"Presently, 125 clinical trials are actively studying the effectiveness of RIC:Intermediate Campath. Out of those investigations, 16 have reached Phase 3; with Philadelphia's being the main hub for these experiments and 1255 other sites running their own tests on this medication."
What criteria must a participant meet in order to be included in this research?
"This research initiative is recruiting 50 individuals with hemoglobinopathies aged 6-25 months. To be considered, patients must have Sickle cell disease; Hemophagocytic lymphohistiocytosis other macrophage activation syndromes; severe Langerhans histiocytosis; Severe combined immune deficiency; adenosine deaminase deficiency and/or common variable immunodeficiency."
What is the predominant purpose of RIC:Intermediate Campath treatment?
"RIC:Intermediate Campath is primarily employed to manage autoimmune hemolytic anemia, but can be utilized in the treatment of multiple sclerosis, transplant rejection; kidney issues and b-lymphocytes."
Has the RIC:Intermediate Campath drug been officially sanctioned by the FDA?
"After a thorough assessment, the team at Power put RIC:Intermediate Campath's safety rating at 2. This trial is still in its Phase 2 stage, meaning there are limited reports of efficacy but data exists supporting safety."
Share this study with friends
Copy Link
Messenger